BioTech/Drugs - Boston, MA, US
Discovering new medicines based on metabolic vulnerabilities in pathological cell populations. Underlying platform uses engineered growth conditions to highlight novel metabolic targets in disease-causing bacteria, lymphocytes, and metastasizing cancer cells. Lead programs in autoimmunity and infectious disease.
Squarespace ECommerce
Gmail
NSOne
Mobile Friendly